Document Detail

Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance.
MedLine Citation:
PMID:  21278618     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Long-term evolution of congenital toxoplasmosis is not documented. We assessed the outcome of treated congenital toxoplasmosis in a cohort of adult individuals who had undergone ante- and postnatal treatment to provide information for pediatricians and parents on the evolution of the disease.
METHODS: We conducted a questionnaire study on 126 adults with congenital toxoplasmosis (mean age: 22.2 years; age range: 18-31 years) monitored regularly until the time of inclusion. The main outcome measures were quality of life (Psychological General Well-Being Index) and visual function (VF14 questionnaire), and the outcomes were correlated with disease-specific factors.
RESULTS: Of the 102 patients (80.9%) who were finally included in the study, 12 (11.8%) presented neurologic effects and 60 (58.8%) manifested ocular lesions; in the latter category, 13 individuals (12.7%) had reduced visual function. The overall global quality-of-life score (74.7 ± 14.2) was close to the expected normal range for the general population (73.7 ± 15.3). Overall, visual function was only slightly impaired (M = 97.3; 95% confidence interval, 95.8-98.8). Although disease-independent critical life circumstances were associated with a reduced Psychological General Well-Being Index, this index was not influenced by any of the clinical characteristics of congenital toxoplasmosis. Neurologic pathologies, reduced visual acuity, foveal location of the retinal lesion, and squinting contributed to decreased visual function at follow-up.
CONCLUSIONS: Our data reveal that treated congenital toxoplasmosis has little effect on the quality of life and visual function of the affected individuals. These encouraging findings may help to alleviate the anxiety of affected individuals and their parents.
François Peyron; Justus G Garweg; Martine Wallon; Elodie Descloux; Muriel Rolland; Jürgen Barth
Related Documents :
15030818 - Posterior capsule opacification after phacoemulsification in patients with postoperativ...
12550118 - Long-term results of facial rejuvenation by carbon dioxide laser resurfacing using a qu...
25459418 - Self-perceived cognitive functioning and its relationship with objective performance in...
21845038 - Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled antich...
9480998 - The use of albuterol in hospitalized infants with bronchiolitis.
22129158 - Update on the third international stroke trial (ist-3) of thrombolysis for acute ischae...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Pediatric infectious disease journal     Volume:  30     ISSN:  1532-0987     ISO Abbreviation:  Pediatr. Infect. Dis. J.     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-15     Completed Date:  2011-09-27     Revised Date:  2011-09-29    
Medline Journal Info:
Nlm Unique ID:  8701858     Medline TA:  Pediatr Infect Dis J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  597-600     Citation Subset:  IM    
Department of Parasitology, Hôpital de la Croix-Rousse, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiprotozoal Agents / administration & dosage*
Cohort Studies
Quality of Life / psychology*
Toxoplasmosis, Congenital / complications*,  drug therapy*
Treatment Outcome
Vision Disorders / epidemiology*,  pathology*
Young Adult
Reg. No./Substance:
0/Antiprotozoal Agents
Comment In:
Pediatr Infect Dis J. 2011 Sep;30(9):816-7; author reply 817   [PMID:  21849862 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate...
Next Document:  Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors.